| By John Funnell | Article Rating: |
|
| October 20, 2009 10:15 AM EDT | Reads: |
1,237 |

Pharmaceutical News on Ulitzer
Once a powerful profit-machine, big pharma is stumbling, the threat of further government intervention, drying product pipelines, fierce competition from generic manufacturers, consumer concerns about safety, and false marketing claims is forcing leaders to revisit operations to secure top line Growth. So leaders such as Judith Marquis, Group VP Genzyme, Jeffrey Nye, Chief Medical Officer J&J Pharmaceuticals and James Kirwin VP Global Clinical Operation Wyeth Pharmaceuticals are uniting with over 50 other figureheads at the renowned NGP US Summit next week in Florida to discuss future technology investments to strengthen the industry and improve efficiency to "weather the Healthcare Reform".
Thomas Haverty - Global VP, Global Clinical Research, Schering-Plough is set to start proceedings and our sources tell us he will be talking about Responding to 21st Century Drug Development Challenge.
"While healthcare reform has dominated headlines, drug companies have come through the debate relatively untouched, but they need to invest wisely to strengthen under the inevitable changes," Drew Contessa NGP US Summit Director.
The good news for the pharmaceutical industry is that it may emerge as a winner in the healthcare reform battle as new customers enter the system and price protections remain in force.
IMS Health, the drug industry forecasting firm, reports that the global pharmaceutical industry will grow 4% to 6% in 2010, up to $825 billion.
It is not very often that the industries elite meet like this and it is clear that significant changes will be outlined as a result.
For more information www.ngpsummit.com.
Published October 20, 2009 Reads 1,237
Copyright © 2009 Ulitzer, Inc. — All Rights Reserved.
Syndicated stories and blog feeds, all rights reserved by the author.
Related Stories
More Stories By John Funnell
John Funnell has worked in online media for ten years, after achieving his First Class BSC Hons Degree and Masters he worked for the BBC before setting up the ‘Beat’ franchise (Beat Club, Beat TV, Beat Mag and Beat Online), utilising the power of Web 2.0 John then set up Clean Living Records Ltd with great success having many acts that charted in Europe. After selling half of the business John looked for a new challenge and joined GDS International as Event Director, forging contacts with some of the biggest technology names in the world, this lead to John having a lead role in the Creation of MeettheBoss.com and MeettheBoss.tv – the largest exclusive Senior executive online network in the world.
- Copenhagen Climate Summit Ends – What Did They Accomplish?
- eHealthcare Social Networking Apps Win
- Employee Driven Sustainability
- Little Shelter Animal Rescue Holiday Donation Drive
- The Good and Not So Good from State of Green Business 2010
- New Hotel Policy: Green, or Disgusting?
- Starting Out With Seeds and Seedlings
- Bridgehead Software Raises Bar for Healthcare Storage Virtualization
- Did Bill O'Reilly and Fox News Contribute to Dr. Tiller's Murder?
- Dr. Leslie Lenert of CDC Speaks on Healthcare IT
- Mobile Healthcare in Developing Countries
- The Cloud Its Benefits and Its Threats
- Virtualization, Cloud Computing and Healthcare Justice
- Pharmaceutical Industry Set to Emerge as winners in the Healthcare Reform
- Google Wave: The Possibilities for Patient-Centered Communication
- Linda Fischetti on VHA Healthcare
- Copenhagen Climate Summit Ends – What Did They Accomplish?
- An Introduction to My Health 2.0 Blog
- Can Health Social Media Learn from Online Dating?
- A Cold, Wet Blanket of Politics Covers the Copenhagen Climate Summit





















Ulitzer content is offered under Creative Commons "Attribution Non-Commercial No Derivatives" License.
For any reuse or distribution, you must make clear to others the license terms of this work.
The best way to do this is with a link to this web page.
Any of the above conditions can be waived if you get written permission from Ulitzer, Inc., the copyright holder.
Nothing in this license impairs or restricts the author's moral rights.